AcuCort AB

AcuCort AB has a highly liquid capital structure, with a current ratio of 4.63, indicating strong short-term liquidity. The company is entirely equity-funded, with no long-term debt and a debt-to-equity ratio of 0.0. However, the company reported negative operating cash flow of -15.95 million SEK and capital expenditures of -2.46 million SEK, suggesting ongoing investment in operations.

Profitability metrics are negative, with a return on equity of -7.45% and a return on assets of -7.06%, both significantly below the industry median for Drug Retailers. The company reported a net loss of -3.80 million SEK and an operating loss of -3.80 million SEK, despite a gross profit of 1.28 million SEK. These results indicate a challenging operating environment and a need for cost optimization or revenue growth to improve returns.

The company does not disclose segment or geographic revenue breakdowns in the latest financial data, making it difficult to assess revenue concentration or geographic exposure. This lack of transparency limits the ability to evaluate diversification or regional risk factors.

Growth trajectory is unclear due to the absence of revenue figures in the latest financial snapshot. However, the company is investing in capital expenditures, which may signal expansion or R&D activities. Without revenue data, it is difficult to assess whether these investments are driving top-line growth or are primarily cost-related.

Risk factors are currently low, with no immediate liquidity or dilution flags detected. The company has no long-term debt and a low dilution risk, with shares outstanding remaining unchanged between basic and diluted shares. However, the negative operating cash flow and net loss suggest potential operational risks that could affect future liquidity if not addressed.

Recent filings and transcripts do not provide additional insight into the company's strategic direction or operational performance. The absence of revenue data and limited disclosure on segments or geographic exposure further constrains the ability to assess recent developments.

AcuCort maintains a zero debt-to-equity ratio, ranking in the top quartile compared to the drug retailer cohort median of 0.38.

The company exhibits strong cash conversion at 4.19, significantly outperforming the drug retailer cohort median of 1.54.

AcuCort faces low dilution risk and low liquidity risk according to the provided risk flag assessments.

Revenue showed slight year-over-year growth of 1.8 percent, increasing from 675,000 SEK to 687,000 SEK.

The company carries a high credit risk flag, signaling potential difficulties in meeting financial obligations.